Story

Replimune Stock Surges on Landmark FDA Approval and $150 Million Capital Raise

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Replimune Stock Surges on Landmark FDA Approval and $150 Million Capital Raise
Text size
Background

Replimune (REPL) stock surged more than 15% in mid-day trading, driven by a convergence of positive catalysts including a recent landmark U.S. Food and Drug Administration (FDA) approval, a newly priced equity offering, and the company's latest quarterly earnings report.

A Trifecta of Positive News

Investors reacted favorably to several key developments that have aligned for the biotechnology firm. The stock climbed 15.3% to $13.90 and touched a new 52-week high of $13.99, a significant recovery from its 52-week low of $1.50.

The rally was propelled by three main factors:

  • FDA Approval: On August 6, the FDA granted accelerated approval for TUDRIQEV, Replimune's oncolytic virus therapy, for a specific type of advanced skin cancer.
  • Capital Raise: The company announced the pricing of a $150 million underwritten public offering to strengthen its balance sheet ahead of the drug's commercial launch.
  • Earnings Catalyst: The company's fiscal Q4 2026 earnings release provided a focal point for the market to price in the recent positive news.

Drug Approval and Strategic Financing

Sample IUX Markets – In-articleAd

The FDA's decision marked a historic milestone, approving TUDRIQEV in combination with Bristol Myers Squibb's nivolumab for adults with advanced cutaneous melanoma that has progressed on prior anti-PD-1 therapy. According to the source, this is the first-ever approval of an oncolytic virus used alongside a checkpoint inhibitor, a significant achievement after the drug was previously rejected twice.

To support the commercialization of TUDRIQEV, which is priced at $450,000 for a full course of treatment, Replimune priced a public offering at $12.06 per share. The deal is expected to generate approximately $140.5 million in net proceeds and is seen by investors as a strategic move to fund the launch rather than a source of dilutive pressure. The offering was underwritten by Leerink Partners, J.P. Morgan, and Cantor Fitzgerald and is expected to close on August 11.

Market Reaction and Analyst Outlook

The stock's strong performance occurred while the broader market was largely flat, underscoring that the gains were driven entirely by company-specific developments. The positive momentum has been supported by Wall Street analysts.

Following the FDA's decision, BMO Capital raised its price target on Replimune to $20, while Wedbush upgraded the stock to Outperform from a Neutral rating. The market's reaction suggests investors are confident in the commercial opportunity for TUDRIQEV, even as the company works to provide confirmatory data from its Phase 3 trials.

Read next

More on Stocks
Back to latest news

LATEST